Pembrolizumab provided clinical benefit in previously treated advanced clear cell gynaecological cancer (CCGC). A single-arm ...

The FDA granted breakthrough therapy status to first-line petosemtamab plus pembrolizumab for PD-L1–positive recurrent or ...

PFS and OS benefits over chemotherapy were maintained for more than 2 years, and many patients had durable responses to ...

Enfortumab vedotin with or without pembrolizumab offers disease control benefits for patients with upper tract urothelial ...

Thomas Hutson, DO, PharmD, discusses key takeaways from the phase 3 CLEAR trial evaluating lenvatinib plus pembrolizumab in ...

Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Thomas E. Hutson, D.O., Pharm.D., Ph.D., chief of the Hematology Oncology Division in the Department of Internal Medicine at Texas Tech University Health Sciences Center (TTUHSC) and director of the ...

A groundbreaking study shows findings that show a treatment can shrink tumors and improve survival outcomes for patients with ...

Topline data were announced from a phase 3 trial evaluating Keytruda plus Lenvima with chemotherapy in advanced gastroesophageal cancer.

The lead investigator for EV-302 said not long ago, survival of 12 to 14 months in this type of bladder cancer was considered ...

First-line treatment with enfortumab vedotin and pembrolizumab provides durable benefits over chemotherapy in advanced urothelial carcinoma.

Pembrolizumab has robust, durable clinical benefit in patients with heavily pretreated CCGC and was tolerated in the overall population,” researchers wrote.